Valley National Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Valley National Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13	Closed	-$5K	–	870
2025 Q4	$5K	Sell	13 -2	-13%	-$885	﹤0.01%	682
2025 Q3	$6K	Buy	+15	New	+$6.11K	﹤0.01%	626
2024 Q3	–	Sell	-25	Closed	-$6K	–	753
2024 Q2	$6K	Buy	25 +10	+67%	+$1.58K	﹤0.01%	709
2024 Q1	$2K	Sell	15 -71	-83%	-$11.8K	﹤0.01%	925
2023 Q4	$16K	Buy	86 +10	+13%	+$1.7K	﹤0.01%	571
2023 Q3	$13K	Buy	76 +1	+1%	+$191	﹤0.01%	557
2023 Q2	$15K	Buy	75 +4	+6%	+$793	﹤0.01%	543
2023 Q1	$15K	Sell	71 -12	-14%	-$2.52K	﹤0.01%	538
2022 Q4	$18K	Buy	83 +3	+4%	+$640	﹤0.01%	502
2022 Q3	$16K	Buy	+80	New	+$15.3K	﹤0.01%	524
2020 Q2	–	Sell	-6	Closed	-$1K	–	770
2020 Q1	$1K	Hold	6	–	–	﹤0.01%	667
2019 Q4	$1K	Sell	6 -6	-50%	-$598	﹤0.01%	699
2019 Q3	$1K	Hold	12	–	–	﹤0.01%	701
2019 Q2	$1K	Hold	12	–	–	﹤0.01%	670
2019 Q1	$1K	Hold	12	–	–	﹤0.01%	670
2018 Q4	$1K	Hold	12	–	–	﹤0.01%	689
2018 Q3	$1K	Sell	12 -11	-48%	-$1.11K	﹤0.01%	617
2018 Q2	$2K	Buy	+23	New	+$2.28K	﹤0.01%	547

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Valley National Advisers's ALNY Position: Q1 2026 in Review

Valley National Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 13 shares — an estimated $5K sold.

Valley National Advisers first reported a position in ALNY in Q2 2018 and held it in 18 quarters. The position peaked at $18K in Q4 2022. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Valley National Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Valley National Advisers sold 13 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5K.
Valley National Advisers first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 18 quarters.
Valley National Advisers's Alnylam Pharmaceuticals position peaked at $18K in Q4 2022.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.